Monoclonal antibodies are effective therapies for many disorders, but their nature and use continues to evolve as technologies emerge to improve their drug-like qualities. In this issue of Structure, Schmitz and colleagues report on structural and biophysical characterizations of single-domain "nanobodies" from llamas that target the epidermal growth factor receptor by both old and new mechanisms.